## 504875137 04/18/2018

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4921877

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
BIOSTRATUM, INC.	05/28/2007

## **RECEIVING PARTY DATA**

Name:	BIOSTRATUM AB	
Street Address:	SANDHAMNSGATAN 23	
City:	STOCKHOLM	
State/Country:	SWEDEN	
Postal Code:	115 28	

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	15409027

#### **CORRESPONDENCE DATA**

**Fax Number:** (312)913-0002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 3129130001

Email: harper@mbhb.com

Correspondent Name: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP

Address Line 1: 300 SOUTH WACKER DRIVE

Address Line 2: SUITE #3100

Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	03-390-USDV4CO3	
NAME OF SUBMITTER:	DAVID HARPER	
SIGNATURE:	/David Harper/	
DATE SIGNED:	04/18/2018	

**Total Attachments: 1** 

source=03-390 Assignment (BioStratum Inc. to BioStratum AB)#page1.tif

PATENT 504875137 REEL: 045578 FRAME: 0362

#### PATENT APPLICATION ASSIGNMENT

WHEREAS, BioStratum, Inc. ("ASSIGNOR"), a Delaware corporation having its principal office at BioStratum, Inc., P.O. Box 575, Alamance, NC 27201, United States of America, owns the following patent applications:

U.S. Patent Application Serial No. <u>10/834,525</u>, filed <u>29 April 2004</u> entitled "ApoCIII and the Treatment and Diagnosis of Diabetes" and

European Patent Application No. <u>04751089.6</u> filed <u>29 April 2004</u> entitled "ApoCIII and the Treatment and <u>Diagnosis of Diabetes"</u>; and

WHEREAS, BioStratum AB. ("ASSIGNEE"), a Swedish corporation, having its principal office at Sandhamnsgatan 23, 115 28 Stockholm, Sweden, desires to acquire the entire right, title and interest in the Application;

NOW, THEREFORE, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers all rights, title and interest in the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues, extensions, or other patent applications claiming the benefit of the filing date of the Applications, to ASSIGNEE, its successors and assigns.

ASSIGNOR hereby authorizes and requests the respective Commissioner of Patents and Trademarks to issue any Letters Patent which may issue for the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and that ASSIGNOR will execute such additional writings and do such additional acts as ASSIGNEE, its successors and assigns, may deem necessary or desirable to perfect its enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reissued, reexamined or extended Letters Patent that may issue from the Application.

BioStratum AB

Date: May 28, 2007

**RECORDED: 04/18/2018** 

Signature:

Printed Name:

EUGEN STEWER

Title: CHAIRMAN, CEO

PATENT REEL: 045578 FRAME: 0363